GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (NAS:VALN) » Definitions » Research & Development

Valneva SE (Valneva SE) Research & Development

: $64.6 Mil (TTM As of Dec. 2023)
View and export this data going back to 2021. Start your Free Trial

Research & Development is the aggregate amount of research and development expenses during the year. Valneva SE's Research & Development for the three months ended in Dec. 2023 was $19.3 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $64.6 Mil.

Valneva SE Research & Development Historical Data

The historical data trend for Valneva SE's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.25 102.74 195.80 111.15 65.32

Valneva SE Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Research & Development Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.29 15.06 12.91 17.33 19.27

Valneva SE Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $64.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valneva SE  (NAS:VALN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Valneva SE Research & Development Related Terms

Thank you for viewing the detailed overview of Valneva SE's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Valneva SE (Valneva SE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (NAS:VALN) » Definitions » Research & Development
Comparable Companies
XPAR:MEDCL XPAR:NANO XPAR:ALSEN XPAR:ALCLS XPAR:IPH XPAR:IVA XPAR:AELIS XPAR:ABVX XPAR:GNFT XPAR:DBV OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
INRLF:USA VLA:France AYJ:Germany VLA:Austria
Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Website
https://www.valneva.com
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.